Krystal(KRYS) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - The company reported Q4 2025 net revenue of $107.1 million, marking a growth of almost 10% compared to the previous quarter and approximately 18% year-over-year [25][26] - Year-to-date net revenue for VYJUVEK reached $389.1 million, an increase of approximately 34% compared to full year 2024 revenue [25] - Gross margin for Q4 was 94%, down from 96% in Q3 2025 and 95% in Q4 2024, attributed to increased sales outside the U.S. which carry higher costs [26] Business Line Data and Key Metrics Changes - VYJUVEK continues to show strong performance with total net revenue since launch exceeding $730 million [6] - The company has signed distributor agreements covering more than 20 countries, aiming to expand to over 40 countries in 2026 [4] - The U.S. market saw over 660 reimbursement approvals, with more than 500 unique prescribers since launch [9] Market Data and Key Metrics Changes - In Europe, over 90 DEB patients have been prescribed VYJUVEK across Germany, France, and Japan, with sustained prescription growth in Germany [11][12] - The launch in Japan has been successful, with a unique distribution model enabling home delivery [13] - Pricing negotiations are ongoing in Germany and France, with expectations for agreements in the second half of 2026 and 2027 respectively [12][14] Company Strategy and Development Direction - The company is focused on expanding global access for VYJUVEK while advancing a disciplined pipeline of gene therapies [5] - Plans to initiate two additional registrational programs in cystic fibrosis and Hailey-Hailey disease later this year [5] - The company aims to build a durable commercial gene therapy business with strong capital allocation and operational improvements [5] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ongoing demand for VYJUVEK, particularly in international markets, which are expected to drive revenue growth in 2026 [30] - The company is aware of the evolving utilization patterns among U.S. patients, shifting towards more intermittent treatment cycles [31] - Management remains optimistic about the potential of their pipeline programs, especially with recent FDA designations that could accelerate development timelines [33] Other Important Information - The company ended the year with $955.9 million in cash and investments, positioning it well for future commercial launches and pipeline milestones [29] - R&D expenses for Q4 were $14.8 million, while SG&A expenses were $41.4 million, reflecting increased headcount and marketing costs [27] Q&A Session Summary Question: Visibility into Q1 and 2026 revenue contribution from U.S. vs. ex-U.S. - Management indicated that while growth will predominantly come from ex-U.S. markets, demand in the U.S. is also accelerating, with expectations to break out revenue in Q1 [36] Question: Data supporting modified dosing regimens for ocular and NK - Management confirmed that the changes were based on patient feedback and the need for home administration, ensuring compliance and convenience [40] Question: Compliance rates in EU and Japan - Compliance in Europe has been consistent with the U.S., while Japan's two-week prescription requirement may affect long-term compliance [46] Question: Updates on pricing negotiations in Europe - Management expects to reach a pricing agreement in Germany in the second half of 2026, while negotiations in France may extend into 2027 [54] Question: Differentiating factors for dosing schedules in ocular studies - The decision for different dosing regimens was based on patient convenience and feedback, with no changes to the dose volume [70]